These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17660718)

  • 1. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.
    McNicholas A; Galloway Y; Stehr-Green P; Reid S; Radke S; Sexton K; Kieft C; Macdonald C; Neutze J; Drake R; Isaac D; O'Donnell M; Tatley M; Oster P; O'Hallahan J
    Hum Vaccin; 2007; 3(5):196-204. PubMed ID: 17660718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
    Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
    Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
    Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
    Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
    Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
    N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
    Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
    Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
    Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
    Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
    Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016.
    Mentzer D; Oberle D; Keller-Stanislawski B
    Euro Surveill; 2018 Apr; 23(17):. PubMed ID: 29717697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlling serogroup B invasive meningococcal disease: the Canadian perspective.
    Bettinger JA; Deeks SL; Halperin SA; Tsang R; Scheifele DW
    Expert Rev Vaccines; 2013 May; 12(5):505-17. PubMed ID: 23659299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness.
    Poolman JT; Richmond P
    Expert Rev Vaccines; 2015; 14(9):1277-87. PubMed ID: 26204792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neisseria meningitidis B vaccines.
    Panatto D; Amicizia D; Lai PL; Gasparini R
    Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.